High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3214-3223

  Berry, Donald A ^a   Ueno, Naoto T ^a   Johnson, Marcella M ^a   Lei, Xiudong ^a   Caputo, Jean ^a   Rodenhuis, Sjoerd ^b   Peters, William P ^c   Leonard, Robert C ^d   Barlow, William E ^e   Tallman, Martin S ^f   Bergh, Jonas ^g   Nitz, Ulrike A ^h   Gianni, Alessandro M ⁱ   Basser, Russell L ^j   Zander, Axel R ^k   Charles Coombes, R ^l   Roché, Henri ^m   Tokuda, Yutaka ⁿ   De Vries, Elisabeth G E ^o   Hortobagyi, Gabriel N ^a   Crown, John P ^p   Pedrazzoli, Paolo ^q   Bregni, Marco ^r   Demirer, Taner ^s   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Regional Consultants in Hematology Oncology   (United States)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h West German Study Group   (Germany)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j ROYAL MELBOURNE HOSPITAL   (Australia)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m INSTITUT CLAUDIUS REGAUD   (France)

ⁿ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^q FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^r SAN RAFFAELE HOSPITAL   (Italy)

^s ANKARA UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PROGESTERONE RECEPTOR; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 80051991350     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5910     Document Type: Article

References (52)

1. National Cancer Institute: High-Dose Chemotherapy for Breast Cancer: History. Washington, DC, National Cancer Institute, 2001. http://www.cancer.gov/ clinicaltrials/developments/high-dose- chemohistory0501
2. Antman KH: New developments in clinical oncology: The interdependence of bench and bed-side. Cancer Res 51:5060s-5064s, 1991 (suppl 18)
3. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
4. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
5. Henderson IC, Berry DA, Demetri GD: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
6. Peters WP, Ross M, Vredenburgh JJ: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
7. Hortobagyi GN, Buzdar AU, Theriault RL, et al: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225-233, 2000
8. Rodenhuis S, Richel DJ, van der Wall E, et al: Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352:515-521, 1998
9. Tallman MS, Gray R, Robert NJ, et al: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349:17-26, 2003
10. Peters WP, Rosner GL, Vredenburgh JJ, et al: Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23:2191-2200, 2005
11. Gianni A, Bonadonna G, Michelangelo Cooperative Group: Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive nodes (LN+). Proc Am Soc Clin Oncol 20:21a, 2001 (abstr 80)
12. Rodenhuis S, Bontenbal M, Beex LV, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7-16, 2003
13. Zander AR, Kröger N, Schmoor C, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 22:2273-2283, 2004
14. Coombes RC, Howell A, Emson M, et al: High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol 16:726-734, 2005
15. Tokuda Y, Tajima T, Narabayashi M, et al: Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 99:145-151, 2008
16. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial-Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000. Erratum in: Lancet 356:2196, 2000
17. Roche H, Viens P, Biron P, et al: High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 10:42-47, 2003
18. Nitz UA, Mohrmann S, Fischer J, et al: Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366: 1935-1944, 2005. Erratum in: Lancet 367:730, 2006
19. Leonard RC, Lind M, Twelves C: Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst 96:1076-1083, 2004
20. International Breast Cancer Study Group, Basser RL, O'Neill A, et al: Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 24:370-378, 2006
21. Moore HC, Green SJ, Gralow JR, et al: Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 25:1677-1682, 2007
22. Albain K, Green S, Rivkin S, et al: Age < 35 years is an adverse prognostic feature in premenopausal node-positive breast cancer patients in Southwest Oncology Group studies. J Clin Oncol 9:35, 1990 (suppl; abstr 32)
23. de la Rochefordiere A, Asselain B, Campana F, et al: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039-1043, 1993
24. Fisher B, Redmond CK, Wickerham DL, et al: Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat 3:355-364, 1983
25. Taylor SG 4th, Knuiman MW, Sleeper LA, et al: Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 7:879-889, 1989
26. Neville AM, Bettelheim R, Gelber RD, et al: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer: The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:696-705, 1992
27. Davis BW, Gelber RD, Goldhirsch A, et al: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662-2670, 1986
28. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95-115, 1985
29. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
30. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
31. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
32. Albain KS, Paik S, van't Veer L: Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18:141-145, 2009 (suppl 3)
33. Berry DA: The difficult and ubiquitous problems of multiplicities. Pharm Stat 6:155-160, 2007
34. Hanrahan EO, Broglio K, Frye D, et al: Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: Follow-up at 12 years. Cancer 106:2327-2336, 2006
35. Schrama JG, Faneyte IF, Schornagel JH, et al: Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Ann Oncol 13:689-698, 2002
36. Zander AR, Schmoor C, Kröger N, et al: Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of follow-up. Ann Oncol 19:1082-1089, 2008
37. Wilking N, Lidbrink E, Wiklund T, et al: Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18:694-700, 2007
38. Colleoni M, Sun Z, Martinelli G, et al: The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: Results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20:1344-1351, 2009
39. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007
40. Hryniuk W, Frei E 3rd, Wright FA: A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity. J Clin Oncol 16:3137-3147, 1998
41. Hryniuk WM, Peters WP, Ragaz J: Determinants of outcome in adjuvant chemotherapy of breast cancer: Dose intensity versus total dose versus dose size. Breast Cancer Res Treat 64:66, 2000 (abstr 66)
42. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York, NY, John Wiley and Sons, 1987
43. Farquhar CM, Marjoribanks J, Lethaby A, et al: High dose chemotherapy for poor prognosis breast cancer: Systematic review and meta-analysis. Cancer Treat Rev 33:325-337, 2007
44. Banna GL, Simonelli M, Santoro A: High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: A critical review. Curr Stem Cell Res Ther 2:65-82, 2007
45. Pedrazzoli P, Rosti G, Secondino S, et al: High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults. Semin Hematol 44:286-295, 2007
46. Rodenhuis S, Bontenbal M, van Hoesel QG, et al: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17:588-596, 2006
47. Elias AD: High dose chemotherapy with stem cell rescue for breast cancer: Current status and future directions. Breast Dis 14:51-68, 2001
48. Marino P, Roche? H, Biron P, et al: Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: The PEGASE 01 Quality of Life Study. Value Health 11:709-718, 2008
49. Berry DA, Ueno NT, Johnson MM, et al: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials. J Clin Oncol 29:3224-3231, 2011
50. Bliss JM, Vigushin D, Kanfer E, et al: Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes (ISRCTN: 52623943). Proc Am Soc Clin Oncol 22:15, 2003 (abstr 58)
51. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in local advanced breast cancer: An EORTC-NCICSAKK multicenter study. J Clin Oncol 21:843-850, 2003
52. Farquhar C, Marjoribanks J, Basser R, et al: High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Sys Rev 3: CD003139, 2005